immunotherapy

Researchers showed that an oral medication can activate worn-out T cells.

Gain insight into how microbiome research is advancing the understanding of cancer biology and therapeutic outcomes.

Living drugs are blurring the line between therapy and biology, challenging decades of assumptions about how medicines are made and controlled.

A first-of-its-kind CAR T treatment helped a woman achieve year-long remission from three severe autoimmune diseases that resisted nine prior therapies.

Scientists have developed a new CAR-T manufacturing method using a multi-cytokine scaffold that produces longer-lived immune cells capable of self-renewal.

Hair loss affects millions, and a new wave of therapies — from drugs to cell-based treatments — could finally offer safe, effective, and lasting solutions.

As drug discovery grows more complex, the pace of discovery increasingly depends on the tools and people working behind the scenes.

With so many cancer patients not responding to these immunotherapies, researchers are looking for new ways to boost their efficacy.

By starting with T cells from healthy donors, Allogene is manufacturing off-the-shelf CAR T cell therapies that patients don’t have to wait for.

Metabolic conditioning is emerging as a powerful strategy to enhance the potency, persistence, and manufacturability of next-generation cell therapies, providing new hope for hard to treat cancers.